pattern cursor banner


This is a combination of a well-established cephalosporin with clinically validated β-lactamase inhibitor. This combination yields ESBL pathogen coverage superior to Piperacillin-Tazobactam and even extending up to some of the CREs such as KPC and OXA 48/181 strains. WCK 4282 demonstrates an attractive potential to minimize the physician’s dependence on carbapenem which is driving the upsurge of CREs and MBLs across the world. Thus, WCK 4282 could fill the crucial product gap between the 3rd/4th generation cephalosporins or Piperacillin-Tazobactam and carbapenems and thereby relieving the pressure of overuse on the last line therapy based on carbapenems.

WCK 4282 : Resistant Pathogen coverage:

  • ESBL Gram negatives including Piperacillin–Tazobactam resistant strains
  • KPC & other CREs with OXA 48/181 β-lactamases resistant to imipenem/meropenem
  • Cefepime resistant Enterobacter with CMY β-lactamase
  • Hyper Amp C expressing ceftazidime/cefepime resistant Pseudomonas
  • Staphylococci, Pneumococci, Streptococci- paediatric skin to sepsis 3 major Gram positives

WCK 4282 : Indication Potential

  • Hospital acquired bacterial Pneumonia (HABP)
  • Blood stream infections and complicated
  • Intra-abdominal and urinary tract infections
  • Complicated Urinary tract Infection (CUTI)


view all